Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pleural Effusion 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Insulin-Like Growth Factor I, Resistance To 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × dalotuzumab × Clear all
NCT00951444 2016-07-06

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00799240 2014-11-07

IMPACT

University of Kansas Medical Center

Phase 2 Completed
27 enrolled
Thoracic

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡